132 related articles for article (PubMed ID: 35780566)
1. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
3. Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease.
Li Y; Jiang G; Wu W; Yang H; Jin Y; Wu M; Liu W; Yang A; Chervova O; Zhang S; Zheng L; Zhang X; Du F; Kanu N; Wu L; Yang F; Wang J; Chen K
EBioMedicine; 2023 May; 91():104553. PubMed ID: 37027928
[TBL] [Abstract][Full Text] [Related]
4. Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma.
Xu Y; Yang Y; Wang Y; Su J; Chan T; Zhou J; Gong Y; Wang K; Gu Y; Zhang C; Wu G; Bi L; Qin X; Han J
J Transl Med; 2023 Apr; 21(1):250. PubMed ID: 37038181
[TBL] [Abstract][Full Text] [Related]
5. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection.
Su S; Xuan Y; Fan X; Bao H; Tang H; Lv X; Ren W; Chen F; Shao Y; Wang T; Wang L
Genomics; 2023 Jul; 115(4):110662. PubMed ID: 37270068
[TBL] [Abstract][Full Text] [Related]
6. Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.
Shi X; Guo S; Duan Q; Zhang W; Gao S; Jing W; Jiang G; Kong X; Li P; Li Y; Teng C; Xu X; Chen S; Nian B; Li Z; Zhong C; Yang X; Zhu G; Du Y; Zhang D; Jin G
J Exp Clin Cancer Res; 2024 May; 43(1):145. PubMed ID: 38750539
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
Xu J; Chen H; Fan W; Qiu M; Feng J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):7. PubMed ID: 38196018
[TBL] [Abstract][Full Text] [Related]
9. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification.
Xu J; Zhang Y; Li M; Shao Z; Dong Y; Li Q; Bai H; Duan J; Zhong J; Wan R; Bai J; Yi X; Tang F; Wang J; Wang Z
EBioMedicine; 2024 Apr; 102():105092. PubMed ID: 38547579
[TBL] [Abstract][Full Text] [Related]
10. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis.
Moldovan N; van der Pol Y; van den Ende T; Boers D; Verkuijlen S; Creemers A; Ramaker J; Vu T; Bootsma S; Lenos KJ; Vermeulen L; Fransen MF; Pegtel M; Bahce I; van Laarhoven H; Mouliere F
Cell Rep Med; 2024 Jan; 5(1):101349. PubMed ID: 38128532
[TBL] [Abstract][Full Text] [Related]
11. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
12. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
13. Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study.
Liu Q; Zhang W; Pei Y; Tao H; Ma J; Li R; Zhang F; Wang L; Shen L; Liu Y; Jia X; Hu Y
BMC Med; 2023 Oct; 21(1):409. PubMed ID: 37904139
[TBL] [Abstract][Full Text] [Related]
14. A Highly Sensitive and Specific Non-Invasive Test through Genome-Wide 5-Hydroxymethylation Mapping for Early Detection of Lung Cancer.
Ren Y; Zhang Z; She Y; He Y; Li D; Shi Y; He C; Yang Y; Zhang W; Chen C
Small Methods; 2024 Mar; 8(3):e2300747. PubMed ID: 37990399
[TBL] [Abstract][Full Text] [Related]
15. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.
Lu D; Wu X; Wu W; Wu S; Li H; Zhang Y; Yan X; Zhai J; Dong X; Feng S; Zhang X; Sun F; Wang S; Cai K
Cell Death Dis; 2023 Dec; 14(12):843. PubMed ID: 38114477
[TBL] [Abstract][Full Text] [Related]
17. High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.
Mahmood K; Jampani P; Clarke JM; Wolf S; Wang X; Wahidi MM; Giovacchini CX; Dorry M; Shofer SL; Shier J; Jones G; Antonia SJ; Nixon AB
Chest; 2023 Jul; 164(1):252-261. PubMed ID: 36693563
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA sequencing for early detection of lung cancer.
Xue R; Yang L; Yang M; Xue F; Li L; Liu M; Ren Y; Qi Y; Zhao J
Expert Rev Mol Diagn; 2023; 23(7):589-606. PubMed ID: 37318381
[TBL] [Abstract][Full Text] [Related]
19. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.
van der Pol Y; Tantyo NA; Evander N; Hentschel AE; Wever BM; Ramaker J; Bootsma S; Fransen MF; Lenos KJ; Vermeulen L; Schneiders FL; Bahce I; Nieuwenhuijzen JA; Steenbergen RD; Pegtel DM; Moldovan N; Mouliere F
EMBO Mol Med; 2023 Dec; 15(12):e17282. PubMed ID: 37942753
[TBL] [Abstract][Full Text] [Related]
20. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
